-
公开(公告)号:US11499163B2
公开(公告)日:2022-11-15
申请号:US16175812
申请日:2018-10-30
Applicant: SUN YAT-SEN UNIVERSITY
IPC: C12N15/85 , C12N15/64 , G01N33/573 , C12N9/64
Abstract: The disclosure relates to an expression method of a Haemocoagulase Acutus (Halase) recombinant protein. The method includes the following steps: (1) optimizing a halase gene; (2) performing Polymerase Chain Reaction (PCR) amplification on an optimized halase gene; (3) constructing an Agkis-pMCX expression vector, transforming plasmids to competent cells of an Escherichia coli for amplification, screening in an Amp-resistant manner for positive cloning, sequencing and extracting recombinant plasmids with correct sequencing; (4) transfecting recombinant plasmids to CHO cells; and (5) expressing the recombinant protein and identifying. According to the expression method, a recombinant halase is expressed first using the CHO cells cultured in a serum-free suspension manner; and by utilizing a bioengineering means, the actual production problems of insufficient raw material sources and unstable quality of a snake venom product are solved successfully.
-
公开(公告)号:US20220031789A1
公开(公告)日:2022-02-03
申请号:US17494858
申请日:2021-10-06
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).
-
3.
公开(公告)号:US20180200319A1
公开(公告)日:2018-07-19
申请号:US15920480
申请日:2018-03-14
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
CPC classification number: A61K36/48 , A61K2236/331 , Y02A50/473
Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).
-
公开(公告)号:US11154582B2
公开(公告)日:2021-10-26
申请号:US15920480
申请日:2018-03-14
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).
-
公开(公告)号:US11793849B2
公开(公告)日:2023-10-24
申请号:US17494858
申请日:2021-10-06
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
CPC classification number: A61K36/48 , A61K2236/331 , Y02A50/30
Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).
-
公开(公告)号:US20190048361A1
公开(公告)日:2019-02-14
申请号:US16175812
申请日:2018-10-30
Applicant: SUN YAT-SEN UNIVERSITY
IPC: C12N15/85 , G01N33/573 , C12N15/64
Abstract: The disclosure relates to an expression method of a Haemocoagulase Acutus (Halase) recombinant protein. The method includes the following steps: (1) optimizing a halase gene; (2) performing Polymerase Chain Reaction (PCR) amplification on an optimized halase gene; (3) constructing an Agkis-pMCX expression vector, transforming plasmids to competent cells of an escherichia coli for amplification, screening in an Amp-resistant manner for positive cloning, sequencing and extracting recombinant plasmids with correct sequencing; (4) transfecting recombinant plasmids to CHO cells; and (5) expressing the recombinant protein and identifying. According to the expression method, a recombinant halase is expressed first using the CHO cells cultured in a serum-free suspension manner; and by utilizing a bioengineering means, the actual production problems of insufficient raw material sources and unstable quality of a snake venom product are solved successfully.
-
公开(公告)号:US11654174B2
公开(公告)日:2023-05-23
申请号:US17494850
申请日:2021-10-06
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
CPC classification number: A61K36/48 , A61K2236/331 , Y02A50/30
Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).
-
公开(公告)号:US20210106640A1
公开(公告)日:2021-04-15
申请号:US17129885
申请日:2020-12-21
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).
-
公开(公告)号:US20210106639A1
公开(公告)日:2021-04-15
申请号:US17129853
申请日:2020-12-21
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).
-
公开(公告)号:US11491198B2
公开(公告)日:2022-11-08
申请号:US17129853
申请日:2020-12-21
Applicant: SUN YAT-SEN UNIVERSITY
IPC: A61K36/48
Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).
-
-
-
-
-
-
-
-
-